JavaScript is at present disabled, this web site works a lot better should you allow JavaScript in your browser.
Log in to MyKarger to verify if you have already got entry to this title.
Purchase
KAB
Purchase a Karger Article Bundle (KAB) and revenue from a reduction!
If you need to redeem your KAB credit score, please log in.
Hire/Cloud
Subscribe
Article / Publication Particulars – “l dopa vitamin b6”
Summary
It has been advised that L-dopa combines with pyridoxine (B6) to type a selected antiparkinsonian molecule. This raises the likelihood that the efficacy of L-dopa will be elevated by giving sufferers each L-dopa and vitamin B6. The administration of B6 to parkinsonian sufferers receiving L-dopa reverses the L-dopa impact. It has been advised that the L-dopa impact just isn’t reversed by B6 in sufferers receiving each L-dopa and a peripheral dopa decarboxylase inhibitor; thus, it’s doable that administration of B6 in giant doses to sufferers receiving this mixture would possibly improve the antiparkinsonian efficacy of L-dopa. To systematically consider this risk, 12 sufferers receiving oral L-dopa and α-methyldopa hydrazine (MK-486), a peripheral dopa decarboxylase inhibitor, got pyridoxine day by day for five–10 days. This failed to extend the antiparkinsonian impact of L-dopa in all 12 sufferers. It additionally did not reverse the L-dopa impact or alter any of the unintended effects. The failure of B6 to reverse the dopa impact confirms the idea that B6 reversal entails peripheral dopa decarboxylase. The failure of enormous quantities of B6 to extend the L-dopa impact casts doubt on the idea {that a} Schiff base shaped of L-dopa and B6 is the precise antiparkinsonian agent mediating the impact of L-dopa.
© 1973 S. Karger AG, Basel
Associated Articles: